Bile acid receptor TGR5 agonism induces NO production and reduces monocyte adhesion in vascular endothelial cells

Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1663-9. doi: 10.1161/ATVBAHA.113.301565. Epub 2013 Apr 25.

Abstract

Objective: TGR5 is a G-protein-coupled receptor for bile acids. So far, little is known about the function of TGR5 in vascular endothelial cells.

Approach and results: In bovine aortic endothelial cells, treatment with a bile acid having a high affinity to TGR5, taurolithocholic acid (TLCA), significantly increased NO production. This effect was abolished by small interfering RNA-mediated depletion of TGR5. TLCA-induced NO production was also observed in human umbilical vein endothelial cells measured via intracellular cGMP accumulation. TLCA increased endothelial NO synthase(ser1177) phosphorylation in human umbilical vein endothelial cells. This response was accompanied by increased Akt(ser473) phosphorylation and intracellular Ca(2+). Inhibition of these signals significantly decreased TLCA-induced NO production. We next examined whether TGR5-mediated NO production affects inflammatory responses of endothelial cells. In human umbilical vein endothelial cells, TLCA significantly reduced tumor necrosis factor-α-induced adhesion of monocytes, vascular cell adhesion molecule-1 expression, and activation of nuclear factor-κB. TLCA also inhibited lipopolysaccharide-induced monocyte adhesion to mesenteric venules in vivo. These inhibitory effects of TLCA were abrogated by NO synthase inhibition.

Conclusions: TGR5 agonism induces NO production via Akt activation and intracellular Ca(2+) increase in vascular endothelial cells, and this function inhibits monocyte adhesion in response to inflammatory stimuli.

Keywords: Akt; TGR5; endothelial NO synthase; inflammation; intracellular Ca2+.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Calcium Signaling / drug effects
  • Cattle
  • Cell Adhesion / drug effects*
  • Coculture Techniques
  • Cyclic GMP / metabolism
  • Dose-Response Relationship, Drug
  • Endothelial Cells / drug effects*
  • Endothelial Cells / immunology
  • Endothelial Cells / metabolism
  • Enzyme Activation
  • Enzyme Inhibitors / pharmacology
  • Human Umbilical Vein Endothelial Cells / drug effects
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Humans
  • Inflammation Mediators / metabolism
  • Lipopolysaccharides / pharmacology
  • Mice
  • Mice, Inbred C57BL
  • Monocytes / drug effects*
  • Monocytes / immunology
  • Monocytes / metabolism
  • NF-kappa B / metabolism
  • Nitric Oxide / metabolism*
  • Nitric Oxide Synthase Type III / antagonists & inhibitors
  • Nitric Oxide Synthase Type III / metabolism
  • Phosphorylation
  • Proto-Oncogene Proteins c-akt / metabolism
  • RNA Interference
  • Receptors, G-Protein-Coupled / agonists*
  • Receptors, G-Protein-Coupled / genetics
  • Receptors, G-Protein-Coupled / metabolism
  • Taurolithocholic Acid / pharmacology*
  • Time Factors
  • Transfection
  • Tumor Necrosis Factor-alpha / metabolism
  • U937 Cells
  • Up-Regulation
  • Vascular Cell Adhesion Molecule-1 / metabolism

Substances

  • Enzyme Inhibitors
  • GPBAR1 protein, human
  • Gpbar1 protein, mouse
  • Inflammation Mediators
  • Lipopolysaccharides
  • NF-kappa B
  • Receptors, G-Protein-Coupled
  • Tumor Necrosis Factor-alpha
  • Vascular Cell Adhesion Molecule-1
  • lipopolysaccharide, E coli O55-B5
  • Nitric Oxide
  • Taurolithocholic Acid
  • NOS3 protein, human
  • Nitric Oxide Synthase Type III
  • Proto-Oncogene Proteins c-akt
  • Cyclic GMP